Suppr超能文献

靶向癌症代谢:饮食与药物干预

Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions.

作者信息

Vernieri Claudio, Casola Stefano, Foiani Marco, Pietrantonio Filippo, de Braud Filippo, Longo Valter

机构信息

Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.

Fondazione Istituto FIRC di Oncologia Molecolare (IFOM), Milan, Italy.

出版信息

Cancer Discov. 2016 Dec;6(12):1315-1333. doi: 10.1158/2159-8290.CD-16-0615. Epub 2016 Nov 21.

Abstract

UNLABELLED

Most tumors display oncogene-driven reprogramming of several metabolic pathways, which are crucial to sustain their growth and proliferation. In recent years, both dietary and pharmacologic approaches that target deregulated tumor metabolism are beginning to be considered for clinical applications. Dietary interventions exploit the ability of nutrient-restricted conditions to exert broad biological effects, protecting normal cells, organs, and systems, while sensitizing a wide variety of cancer cells to cytotoxic therapies. On the other hand, drugs targeting enzymes or metabolites of crucial metabolic pathways can be highly specific and effective, but must be matched with a responsive tumor, which might rapidly adapt. In this review, we illustrate how dietary and pharmacologic therapies differ in their effect on tumor growth, proliferation, and metabolism and discuss the available preclinical and clinical evidence in favor of or against each of them. We also indicate, when appropriate, how to optimize future investigations on metabolic therapies on the basis of tumor- and patient-related characteristics.

SIGNIFICANCE

To our knowledge, this is the first review article that comprehensively analyzes the preclinical and preliminary clinical experimental foundations of both dietary and pharmacologic metabolic interventions in cancer therapy. Among several promising therapies, we propose treatment personalization on the basis of tumor genetics, tumor metabolism, and patient systemic metabolism.Cancer Discov; 6(12); 1315-33. ©2016 AACR.

摘要

未标注

大多数肿瘤表现出由癌基因驱动的多种代谢途径重编程,这些途径对于维持肿瘤的生长和增殖至关重要。近年来,针对失调的肿瘤代谢的饮食和药物治疗方法开始被考虑用于临床应用。饮食干预利用营养限制条件发挥广泛生物学效应的能力,保护正常细胞、器官和系统,同时使多种癌细胞对细胞毒性疗法敏感。另一方面,针对关键代谢途径的酶或代谢物的药物可能具有高度特异性和有效性,但必须与可能迅速适应的反应性肿瘤相匹配。在本综述中,我们阐述了饮食和药物疗法在对肿瘤生长、增殖和代谢的影响方面有何不同,并讨论了支持或反对它们的现有临床前和临床证据。我们还在适当的时候指出,如何根据肿瘤和患者相关特征优化未来关于代谢疗法的研究。

意义

据我们所知,这是第一篇全面分析癌症治疗中饮食和药物代谢干预的临床前和初步临床实验基础的综述文章。在几种有前景的疗法中,我们建议根据肿瘤遗传学、肿瘤代谢和患者全身代谢进行治疗个性化。《癌症发现》;6(12);1315 - 33。©2016美国癌症研究协会。

相似文献

1
Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions.
Cancer Discov. 2016 Dec;6(12):1315-1333. doi: 10.1158/2159-8290.CD-16-0615. Epub 2016 Nov 21.
2
Targeting Cell Metabolism as Cancer Therapy.
Antioxid Redox Signal. 2020 Feb 10;32(5):285-308. doi: 10.1089/ars.2019.7947. Epub 2019 Dec 16.
3
Glutaminolysis as a target for cancer therapy.
Oncogene. 2016 Jul 14;35(28):3619-25. doi: 10.1038/onc.2015.447. Epub 2015 Nov 23.
5
Oncogene-directed alterations in cancer cell metabolism.
Trends Cancer. 2016 Jul;2(7):365-377. doi: 10.1016/j.trecan.2016.06.002. Epub 2016 Jun 27.
6
Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy.
Molecules. 2020 Oct 20;25(20):4831. doi: 10.3390/molecules25204831.
7
Navigating metabolic pathways to enhance antitumour immunity and immunotherapy.
Nat Rev Clin Oncol. 2019 Jul;16(7):425-441. doi: 10.1038/s41571-019-0203-7.
8
Cholesterol metabolism: New functions and therapeutic approaches in cancer.
Biochim Biophys Acta Rev Cancer. 2020 Aug;1874(1):188394. doi: 10.1016/j.bbcan.2020.188394. Epub 2020 Jul 19.
9
The Emerging Hallmarks of Cancer Metabolism.
Cell Metab. 2016 Jan 12;23(1):27-47. doi: 10.1016/j.cmet.2015.12.006.
10
Iron as a Central Player and Promising Target in Cancer Progression.
Int J Mol Sci. 2019 Jan 11;20(2):273. doi: 10.3390/ijms20020273.

引用本文的文献

1
Prognostic Significance of the Comprehensive Biomarker Analysis in Colorectal Cancer.
Life (Basel). 2025 Jul 14;15(7):1100. doi: 10.3390/life15071100.
2
Serum metabolic profiling enables diagnosis, prognosis, and monitoring for brainstem gliomas.
Nat Commun. 2025 Jul 3;16(1):6108. doi: 10.1038/s41467-025-61163-9.
7
Oxidative phosphorylation and breast cancer progression: insights into PGC-1α's role in mitochondrial function.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar 17. doi: 10.1007/s00210-025-04018-w.
10
CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer.
J Exp Clin Cancer Res. 2025 Jan 20;44(1):19. doi: 10.1186/s13046-025-03276-z.

本文引用的文献

2
Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion.
Nature. 2016 Aug 25;536(7617):479-83. doi: 10.1038/nature19084. Epub 2016 Aug 10.
3
Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance.
Cancer Cell. 2016 Jul 11;30(1):147-160. doi: 10.1016/j.ccell.2016.05.016.
4
Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity.
Cancer Cell. 2016 Jul 11;30(1):136-146. doi: 10.1016/j.ccell.2016.06.005.
5
Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer.
Nat Commun. 2016 Jun 20;7:11971. doi: 10.1038/ncomms11971.
6
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.
Cancer Discov. 2016 Jul;6(7):727-39. doi: 10.1158/2159-8290.CD-15-1442. Epub 2016 May 26.
7
IDH mutations in cancer and progress toward development of targeted therapeutics.
Ann Oncol. 2016 Apr;27(4):599-608. doi: 10.1093/annonc/mdw013.
9
Methionine and Kynurenine Activate Oncogenic Kinases in Glioblastoma, and Methionine Deprivation Compromises Proliferation.
Clin Cancer Res. 2016 Jul 15;22(14):3513-23. doi: 10.1158/1078-0432.CCR-15-2308. Epub 2016 Mar 2.
10
Environment Impacts the Metabolic Dependencies of Ras-Driven Non-Small Cell Lung Cancer.
Cell Metab. 2016 Mar 8;23(3):517-28. doi: 10.1016/j.cmet.2016.01.007. Epub 2016 Feb 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验